Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
December 2024 Update: There is a significant development concerning eye-related side effects of Ozempic and other semaglutide drugs. Two large medical studies from Denmark presented more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness.
These two recent studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss.
And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
A 2025 medical study considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to other antidiabetic medications. The researchers concluded that there is an Ozempic and Mounjaro increased risk of NAION.
A new medical article published in August 2025 had an important drug safety bottom-line statement: “In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed [Ozempic (semaglutide)] or [Mounjaro (tirzepatide)] had an increased risk of NAION…”.
To read more of this article, click below:
From the Discussion part of this recent medical journal article published August 11, 2025, online by JAMA Network Open, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“:
In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that semaglutide [(Ozempic)] or tirzepatide [(Mounjaro)] compared with other antidiabetic medications was associated with a differential risk of optic nerve and visual pathways, including increased risk of NAION and other optic nerve disorders, but not optic neuritis, papilledema, optic atrophy, or optic disc orders. Cumulative incidence curves began to diverge immediately after medication initiation and continued to separate thereafter.
Related to this Ozempic and Mounjaro increased risk of NAION finding, we point out that there are additional drugs not used for diabetes but for obesity and weight loss purposes that contain semaglutide (Wegovy, Rybelsus) or tirzepatide (Zepbound). As we have covered in earlier articles, there is some evidence that the NAION eye-related side effect is associated with those additional drugs, too.
We will continue to follow the Ozempic and Mounjaro increased risk of NAION drug safety issue, as well as whether the two other semaglutide-containing drugs (Wegovy, Rybelsus) and the one other tirzepatide-containing drug (Zepbound) are associated with an increased risk of NAION.
[Read the article in full at source]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages